



# T-ALL's Achilles' Heel: Disrupting the UPR for Therapeutic Gain

Shani Mistriel Zerbib, Nira Twaik, Leonor Daniel and Michael Berger



## Is UPR Disruption a Therapeutic Strategy for T-ALL?




#### Cracking the Mechanism

leukemic burden and


improved survival in vivo

BIX Influences T-ALL Independently of BiP Overexpression



BIX Targets UPR Functionality in T-ALL, Not in A431 Cells

promising therapeutic strategy



T-ALL cells recover from Tunicamycin-induced ER stress, showing a functional UPR. BIX disrupts this balance, with a synergistic effect in T-ALL but not A431

### BIX increases nuclear ATF6 degradation, altering UPR signaling

#### Preclinical Findings: BIX Disrupts T-ALL Progression Thy1.2 GFP cells in blood BIX treatment - T-ALL mice model before and after bix treatment Leukemic SC transplantation Vehicle only End of for recipient 40-**Ponceau** 3.25mg/kg experiment # 30-21.74 20-30-→ 7.5mg/kg before Conclusions Recipient mice irradiation 280rad time (week) BIX BIX W4 W5 W6 W7 D-1 D0 ATF6 PERK ATF6 PERK IRE1 Bix treatment survival curve 1111 leukemic bone marrow model Probability of Survival Targeting UPR homeostasis via **BIX** treatment **reduced**

20

Time (d)

40

60

BIX amplifies ATF6 degradation thus impairing T-ALL survival This work provides a basis for exploring **UPR** modulation as a strategy for T-ALL therapy So, Step into my shoes to play with the **UPR! ATF6** selectively impairs T-ALL progression, identifying it as a



ATF6 PERK IRE1